Baclofen Setback Forces Sun R&D Arm Towards Difficult Choices

Sun Pharma Advanced Research Company’s baclofen GRS has failed to meet its primary endpoint in a US Phase III study, posing several tough questions for the firm. It may have to advance partnering plans for some assets and also review its cash flow situation closely.

Paths — SPARC MAY HAVE TO MAKE SOME TOUGH CHOICES IN VIEW OF THE STUDY SETBACK

Sun Pharma Advanced Research Co. Ltd.’s (SPARC) baclofen GRS for the treatment of spasticity in patients with multiple sclerosis has failed to meet its primary endpoint in placebo controlled studies in the US, casting a shadow on the firm’s short-term outlook. SPARC is the listed spin-off R&D arm of India’s top-ranked pharma company, Sun Pharmaceutical Industries Ltd..

SPARC’s management admitted that the study outcome would impact the firm’s ability to “prosecute its clinical agenda fully”, but underscored...